Nuvation Bio Inc. (NUVB)
- Previous Close
3.4100 - Open
3.4100 - Bid 3.2200 x 3100
- Ask 3.3100 x 3000
- Day's Range
3.2800 - 3.4650 - 52 Week Range
0.9500 - 4.1600 - Volume
806,061 - Avg. Volume
1,510,968 - Market Cap (intraday)
823.928M - Beta (5Y Monthly) 1.42
- PE Ratio (TTM)
-- - EPS (TTM)
-0.3200 - Earnings Date Aug 1, 2024 - Aug 5, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
5.90
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.
www.nuvationbio.comRecent News: NUVB
Performance Overview: NUVB
Trailing total returns as of 5/17/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NUVB
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NUVB
Valuation Measures
Market Cap
823.93M
Enterprise Value
230.48M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.39
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-9.20%
Return on Equity (ttm)
-11.15%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-68.87M
Diluted EPS (ttm)
-0.3200
Balance Sheet and Cash Flow
Total Cash (mrq)
596.98M
Total Debt/Equity (mrq)
0.60%
Levered Free Cash Flow (ttm)
-41.27M
Research Analysis: NUVB
Company Insights: NUVB
NUVB does not have Company Insights